Clinical trials: Safety in Healthy Adults
Healthy Participants
A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)
The goal of this clinical study is to learn if giving repeated annual doses of MK-1406 (CD388) is safe and how the body reacts to it in healthy adults who have already received one dose without serious side effects.
- Trial name
- NAVIGATE-2 (NCT07225959)
- Testing
- MK-1406 Injection
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Rabies
Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell)
To describe the immunogenicity and safety of two dosages of Sinovac rabies vaccine, as well as compared the differences with the marked WHO PQ rabies vaccine Verorab® in a post-exposure prophylaxis (PEP) schedule.
- Trial name
- NCT07055880
- Testing
- Rabies Vaccine (Serum-free Vero Cell), Freeze-dried, Verorab®
- Where
- Pakistan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Healthy Adult Male and Female Volunteers, Mild Dyslipidemia
EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia
EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting ANGPTL3, which may bring benefits for patients with dyslipidemia conditions.
- Trial name
- NCT07412080
- Testing
- EDP167
- Where
- 2 sites in China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eddingpharm (Zhuhai) Co., Ltd.
Healthy Subjects
Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine
This is a Phase 1, single-center, nonrandomized, open-label, 2-part, fixed-sequence, drug-drug interaction (DDI) study to assess the effect of multiple doses of itraconazole, a CYP3A4 enzyme inhibitor, on the single dose PK of…
- Trial name
- NCT05486949
- Testing
- AZD4205 and carbamazepine, AZD4205 and itraconazole
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Dizal Pharmaceuticals
Safety and Tolerability
Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers
This study will test single doses of the study drug in increasing amounts to see if it is safe.
- Trial name
- NCT01952548
- Testing
- K-312
- Where
- United States
- Sponsor
- Kowa Research Institute, Inc.
Healthy Volunteers
A Trial to Learn How BAY1817080 Moves Into, Through and Out of the Body and How Safe it is in Healthy Chinese Men
Researchers are looking for a better way to treat chronic cough. Before patients with medical conditions can join clinical trials, researchers do trials in healthy participants first to understand how the body acts on the new…
- Trial name
- NCT04802343
- Testing
- BAY1817080
- Where
- China
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Bayer
Drug Kinetics
Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Effects of Food on the Pharmacokinetics and Safety of Orally Administered Radotinib in Healthy Adults
- Trial name
- NCT06461078
- Testing
- Radotinib HCl
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Healthy
A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects
Study design: Phase I, first-in-human, randomized, double-blind, placebo-controlled, sequential dose escalation study of intravenously administered HM10760A in healthy adult Caucasian and Japanese subjects.
- Trial name
- EPO (NCT01030315)
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Health Adult Subjects
A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult
he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to…
- Trial name
- NCT07199270
- Testing
- GR2303 injection
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Male Contraception, Healthy Male Adults
A First in Human Study, Evaluating the Safety and Efficacy of ADAM™ 1.0
This study will evaluate the safety and feasibility of the ADAM System for implantation into the vas deferens in 25 healthy males at 3 sites. This is a prospective, non-randomized, open label interventional trial.
- Trial name
- NCT05134428
- Testing
- ADAM System
- Where
- 3 sites in Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Contraline, Inc
Healthy Volunteer, Becker Muscular Dystrophy
A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults
EDG-5506 is an investigational product intended to protect and improve function of dystrophic muscle fibers. This Phase 1 study of EDG-5506 will assess the safety, tolerability, and pharmacokinetics (PK) and of EDG-5506 in adult…
- Trial name
- NCT04585464
- Testing
- EDG-5506
- Where
- United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Edgewise Therapeutics, Inc.
Diabetes Mellitus
Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants
The purpose of this study is to determine the safety and tolerability of NGM282, both single dose and multiple doses, in normal healthy adult participants.
- Trial name
- NCT01776528
- Testing
- NGM282
- Where
- Australia
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- NGM Biopharmaceuticals, Inc
COVID-19, SARS-CoV-2
Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)
This study is to evaluate the safety, reactogenicity, and immunogenicity of the QTP104 vaccine against SARS-CoV-2 infection in healthy adults.
- Trial name
- NCT05876364
- Testing
- QTP104 1ug, QTP104 5ug, QTP104 25ug
- Where
- 2 sites in South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Quratis Inc.
Drug Combination, Pharmacokinetics
Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects
Primary Objective To evaluate the safety and tolerability of co-administered single dose Dihydroartemisinin-Piperaquine (DHA-PQP), Ivermectin (IVM), Primaquine (PQ), and Albendazole (ABZ) in healthy subjects.
- Conditions
- Drug Combination, Pharmacokinetics, Healthy
- Trial name
- NCT02568098
- Testing
- IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ, PQ and DHA-PQP and PQ, DHA-PQP
- Where
- Thailand
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Age-related Macular Degeneration
QA102 Phase 1 Study in Healthy Young and Older Adult Subjects
This will be a double masked, randomized, placebo controlled, single and multiple oral dose study conducted in 3 parts. The safety and tolerability of single and multiple ascending oral doses of QA102 in healthy young and older…
- Trial name
- NCT04894071
- Testing
- QA102
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Smilebiotek Zhuhai Limited
Healthy
A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
The goal of the study is to learn what happens to different doses and forms of Embibatinib in a healthy person's body over time.
- Trial name
- NCT07838987
- Testing
- Embibatinib, Rabeprazole, Midazolam
- Where
- United States
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Idiopathic Pulmonary Fibrosis
Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects
The current study will investigate the initial safety, tolerability, and PK profile of inhaled LTI-03 in healthy volunteers. In order to minimize exposure, the study will first test single ascending doses (SAD) of LTI-03 followed…
- Trial name
- NCT04233814
- Testing
- Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03)
- Where
- United Kingdom
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Rein Therapeutics
Respiratory Synctial Virus Infections
A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults
The purpose of this first time in human (FTiH) study is to assess the safety, reactogenicity and immunogenicity of 2 doses of the RSV investigational vaccine, when administered intramuscularly according to a 0, 1 month schedule…
- Trial name
- NCT02491463
- Testing
- GSK3389245A_LD GROUP, GSK3389245A_HD GROUP, Bexsero
- Where
- United Kingdom
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers
The purpose of the study is to evaluate the pharmacokinetics and safety of 3 single doses of Methylphenidate HCl in healthy Japanese adult male volunteers.
- Trial name
- NCT01202734
- Testing
- Methylphenidate HCl
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics properties of TNM002 following a single intramuscular dose in Chinese healthy adults.
- Trial name
- NCT05842798
- Testing
- TNM002
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.